Article and Video CATEGORIES

Cancer Journey

Search By

Cesar A. De Las Casas, MD, MPH, board-certified hematologist and oncologist. He earned his medical degree from the Universidad Peruana Cayetano Heredia in Lima in 1994. He completed his internship in internal medicine at the Baylor College of Medicine in 1999, serving as Chief Medical Resident at St. Luke’s Episcopal Hospital in Houston and at Ben Taub Hospital in 1999 and 2000.

Spanish Blood Cancer Library - Should all patients receive an autologous transplant?
dbrock
¿Todos deberían de recibir un trasplante autólogo?
Author
Cesar A. De Las Casas, MD, MPH, GRACE Faculty

GRACE sat down with Cesar A. De Las Casas, MD, MPH, to discuss information regarding whether all patients should receive an autologous transplant (¿Todos deberían de recibir un trasplante autólogo?). Stay tuned for more on our continuing video series with our Spanish speaking faculty on updates in blood cancer treatments, and Multiple Myeloma, (Mieloma Múltiple).


 

We would like to thank the following company for their support of this program:

 


 

Video Language

Next Previous link

Previous PostNext Post

Related Content

Online Community

An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:

  1. The antibody, which serves as the “horse,” specifically targets a protein found on cancer...

Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...

The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)

There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...

Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.

The...

Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...

Hi Stan!  So good to hear from you.  I'm sorry for the late response.  I too have been out of town with family and missed your post, probably because I was...

It is so good to hear from you!  And I am so happy to hear that your holidays have been good and that you are doing well.  It sounds like your...

Recent Comments

JOIN THE CONVERSATION
Biomarkers
By JanineT GRACE … on
Radiation Therapy
By JanineT GRACE … on
Oligometastatic vs Oligoprogression
By JanineT GRACE … on
Hi Stan!! and happiest of holidays!
By dbrock on